pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,987 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1388Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls113
therapy area
allOncology12306Rare Disease3217Immunology2862Cardiology2745Hematology2177Pulmonology2138Vaccines
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 5mo agoNegative↗ source
  • City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt disease
    City Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
    BioPharma Dive · 5mo agoDealPositive↗ source
← prev
page 128 of 160
next →
fda medwatch111
globenewswire health73
fda press59
1796
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy
    Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
    Endpoints · 5mo agoDealPositive↗ source
  • City Therapeutics raises $99.5 million to advance three RNAi drug candidates
    City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…
    Endpoints · 5mo agoDealPositive↗ source
  • GoHealth files for Chapter 11 bankruptcy as Medicare Advantage insurers retreat
    GoHealth, a health‑insurance marketplace that serves seniors, voluntarily filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court. The filing follows a period of volatility in the Medicare Ad…
    Endpoints · 5mo agoNegative↗ source
  • Tango Therapeutics reports strong early response with vopimetostat plus daraxonrasib in pancreatic cancer trial
    Tango Therapeutics announced that its experimental epigenetic drug vopimetostat, when combined with Revolution Medicines' KRAS inhibitor daraxonrasib, produced high response rates in a small pancre…
    BioPharma Dive · 5mo agoPositive readoutPositive↗ source
  • GSK partners with Engitix on multi-target liver research
    GSK announced a collaboration with London-based Engitix to explore multiple targets for liver disease. Engitix will apply its extracellular matrix-based disease models to uncover new therapeutic op…
    Endpoints · 5mo agoDealNeutral↗ source
  • Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition
    Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
    STAT · 5mo agoNeutral↗ source
  • Cavalry Biosciences seeks $75M Series B to advance eye and muscle disorder candidates
    Cavalry Biosciences, the first company emerging from the Jupiter Bioventures incubator, announced it is pursuing a $75 million Series B financing round. The capital is intended to move its first t…
    Endpoints · 5mo agoDealPositive↗ source
  • Tango and Revolution report high response rates in early pancreatic cancer combo trial
    Tango Therapeutics and Revolution Medicines tested a combination of Tango's drug vopimetostat with Revolution's daraxonrasib in an early-stage clinical trial for pancreatic cancer. The study enroll…
    STAT · 5mo agoPositive readoutPositive↗ source
  • Takeda braces for $2.5 billion charge after losing Amitiza antitrust case, plans appeal
    Takeda Pharmaceutical has revised its financial outlook to include a potential $2.5 billion charge stemming from a recent antitrust lawsuit loss involving its laxative product Amitiza. The US Dist…
    Endpoints · 5mo agoRegulatoryNegative↗ source
  • Biopharma must pair innovation with operational readiness to scale therapies
    The article argues that breakthrough science alone no longer guarantees success in biopharma. Companies now face pressure to turn discoveries into reliably manufactured, delivered, and scalable pro…
    BioPharma Dive · 5mo agoNeutral↗ source
  • UnitedHealthcare reduces reimbursement for lactation counseling, sparking provider backlash
    UnitedHealthcare announced a change to its payment policy for lactation counseling services. The new policy would lower or eliminate reimbursement for many providers who offer these services, prom…
    STAT · 5mo agoRegulatoryNegative↗ source
  • Novo Nordisk aims to bring triple-G obesity injection to market by 2030
    Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…
    Endpoints · 5mo agoPositive↗ source
  • Logistics firms tackle time-critical delivery of radiopharmaceuticals for cancer care
    Radiopharmaceuticals are emerging as a key tool in oncology, offering cell‑level targeting that spares healthy tissue while delivering radiation directly to tumors. Because the radioactive isotope…
    BioPharma Dive · 5mo agoPositive↗ source
  • Mass General launches mobile vascular clinic to treat unhoused patients and prevent amputations
    Unhoused individuals often face untreated vascular problems that can quickly lead to severe wounds and the risk of losing a limb. Limited access to regular medical care leaves many without timely i…
    STAT · 5mo agoPositive↗ source
  • ADA conference sees data presentations and police escort of members over editorial distribution
    The American Diabetes Association held its annual meeting in New Orleans, concluding three days of sessions that featured new data readouts and scientific presentations. Attendees heard updates on…
    STAT · 5mo agoNeutral↗ source
  • Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025
    Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025. For the first time in four years the publication raised the minimum compensation threshold…
    Endpoints · 5mo agoNeutral↗ source
  • Biopharma pay series to return with new installments
    The publisher announced that new installments of its biopharma pay series will be released in the near future. The series traditionally examines compensation trends and salary data across the phar…
    Endpoints · 5mo agoNeutral↗ source
  • U.S. horses face obesity epidemic mirroring human rates
    A recent peer‑reviewed study found that about 51% of mature light‑breed horses in the United States are obese, a prevalence that ranks among the world’s highest and exceeds rates in Britain, Austra…
    STAT · 5mo agoNegative↗ source
  • Nearly one in five patients stopped Boehringer's obesity shot in Phase 3 trial because of side effects
    Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, was evaluated in the Phase 3 SYNCHRONIZE-1 study. The trial reported that 19% of participants discontinued the treatm…
    Endpoints · 5mo agoNegative readoutNegative↗ source
  • Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight loss
    Data from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…
    STAT · 5mo agoNegative readoutNegative↗ source
  • STAT roundup highlights obesity drug competition and other ADA conference updates
    STAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…
    STAT · 5mo agoNeutral↗ source
  • Pfizer's Berobenatide GLP-1 injection shows efficacy in obesity and diabetes in early data
    Pfizer presented early data on its long-acting GLP-1 injection, Berobenatide, at a conference on June 6, 2026. The results indicated the drug was effective in patients who have both obesity and d…
    Endpoints · 5mo agoPositive readoutPositive↗ source
  • Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesity
    Roche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…
    Endpoints · 5mo agoCRLPositive↗ source